Anavex Life Sciences Corp (AVXL)

[end2war]

Roughly 80 percent of potential Aduhelm patients are old enough to receive Medicare, making the program’s coverage decision crucial. Private insurers often follow Medicare’s lead.

Medicare almost always pays for F.D.A.-approved drugs, at least for the medical conditions designated on their label, health policy experts said. But with Aduhelm, Medicare officials have undertaken a monthslong review that could result in no coverage, full coverage or limited coverage.

The New York Times: Alzheimer's Drug Aduhelm Faces Crucial Medicare Decision.
https://www.nytimes.com/2021/12/31/health/aduhelm-alzheimers-medicare.html